阿斯利康与百时美施贵宝计划合并？解析其利弊 (NYSE:AZN)
· seekingalpha.com
关于阿斯利康 (AstraZeneca) 与百时美施贵宝 (Bristol Myers Squibb) 巨头合并的传闻甚嚣尘上：专利悬崖、肿瘤学协同效应以及关键风险——立即获取股票分析要点。
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...